In recent paper published in Rheumatology, authors Till Uhlig, MD, and Guro L. Goll, PhD explore some of the remaining barriers to the adoption of biosimilar therapies in Europe. Physician attitudes, patient concerns, and prescribing restrictions on biologic therapies are all identified in the paper as having a role curbing uptake of biosimilars.
In recent paper published in Rheumatology, authors Till Uhlig, MD, and Guro L. Goll, PhD explore some of the remaining barriers to the adoption of biosimilar therapies in Europe. Physician attitudes, patient concerns, and prescribing restrictions on biologic therapies are all identified in the paper as having a role curbing uptake of biosimilars.
The authors point to a Web-based survey of the European Crohn’s and Colitis Organization, a non-profit organization comprising clinicians who treat inflammatory bowel disease, which showed that, while there existed a high level of awareness of biosimilars and their potential advantages in gastroenterology indications, only 24% of respondents pledged their faith in extrapolating a biosimilar’s indications. Furthermore, 61% said that they had little or no confidence in using biosimilars in their clinical practice. Another study (which included US and European respondents) found that only 47% of respondents believed that biosimilars were safe and effective enough for them to feel comfortable to prescribe, while 43% said that they needed more information about biosimilars.
Patients, too, continue to lack adequate education on biosimilars. The authors report that patients have concerns about pharmacovigilance, interchangeability, switching, and substitution, and that these concerns were cause for both skepticism and anxiety about using biosimilars. They also report that the switch to a biosimilar has been associated with the possibility of a nocebo effect, in which negative expectations of a therapy produce detrimental results.
Furthermore, access to biologic therapies varies across European health systems. As Sonia T. Oskouei notes in a recent contribution to The Center for Biosimilars®, government involvement, reimbursement systems, and tender procurement policies vary by nation. The authors note a correlation between higher socioeconomic status and access to biologics; specifically, 40% of patients with rheumatoid arthritis (RA) in Europe (approximately 320 million patients) face severe restrictions on their access to biologic therapies. These restrictions are primarily financial, administrative, and prescribing-related; in the 36 countries where biologics are reimbursed, clinical criteria regulate which patients may initiate treatment. In 56% of these countries, a Disease Activity Score 28 scale score (DAS28) of 3.2 or higher was a clinical requirement to initiate treatment with biologics. In 61% of these countries, patients were required to have tried more than 1 traditional disease modifying anti-rheumatic drug before being treated with a biologic.
European nations outside the European Union generally had stricter rules for initiating biologics than were recommended by the European League Against Rheumatism (EULAR), the authors note, and in countries with spending limitations, early RA treatment is less likely. Additionally, cost pressure may prevent patients from receiving the most appropriate treatments.
The authors say that European prescribing practices and regulations will need to change in order to take advantage of the opportunity that biosimilar therapies provide in reducing treatment costs while reducing disparities in access to biologics.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.